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Abstract
Patients with demyelinating diseases (DDs) such as multiple sclerosis have a 20-fold higher risk of developing
trigeminal neuralgia (TN). DD-related TN is more frequently refractory to the usual medical and surgical treatment.
We report the case of a 57-year-old man presenting to our neurology outpatient clinic with a 12-year history of
medical and surgical refractory TN associated with demyelinating lesions on magnetic resonance imaging. After a
new failure of pharmacological treatment with oxcarbazepine, pregabalin, baclofen, and duloxetine, motor cortex
stimulation (MCS) was performed, and the patient remained mostly pain-free, without any pharmacological treat-
ment during the 3.5 years of follow-up. MCS may be a useful approach for DD-related refractory TN, and further
studies can clarify its role in TN management.
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Introduction
Trigeminal neuralgia (TN) is an uncommon cause of facial
pain affecting less than 0.1% of the general population.1
However, patients with demyelinating diseases (DDs) such
as multiple sclerosis (MS) have a 20-fold higher risk of
developing TN.2 TN can occur either in classical form,
mostly related to a neurovascular contact, or in symptomatic
form like the one related to DDs.3 However, the sympto-
matic form could be even more complicated—that is, a high
proportion of patients with DD-related TN were found to
have simultaneously a pontine plaque coexisting with a neu-
rovascular compression. This led to the proposal of a double-
crush mechanism, where increased neuronal susceptibility to
ectopic excitation due to demyelination coexists with a vas-
cular compression.4 Probably this contributes to DD-related
TN being harder to manage pharmacologically and surgi-
cally, with lower response rates than classical TN.5
It becomes, therefore, necessary to consider different
treatment for patients with refractory DD-related TN. We
report the case of a refractory TN in a patient with a
clinically isolated syndrome (CIS) that was treated with
motor cortex stimulation (MCS) with a good outcome
(3.5 years of follow-up). Informed consent was obtained
for the case report.
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Case report
A 57-year-old man presented to our neurology outpatient
clinic with a 12-year history of paroxysmal and jolt-like
episodes of right facial pain (affecting the territories of V2
and V3) associated with face movement, facial touch, and
masticatory movements.
His magnetic resonance imaging (MRI) disclosed
spinal, infratentorial, juxtacortical, and periventricular
hyperintense T2 lesions suggestive of a primary DD.
Besides the TN, there were no other clinical episodes sug-
gesting MS (per Polman definition) and the lesions pre-
sented no radiological progression up to 5 years from the
original MRI (Figure 1(a) to (e)). A diagnosis of CIS was
done at the time, and no MS disease-modifying drug was
initiated. Complementary immunological testing was neg-
ative. No lumbar puncture was performed at the time (No
clinical relapses were documented nor imagiological
progression. According to the MS criteria used at the time
- McDonald 2010 - paraclinical findings as positive
cerebrospinal fluid would not change the diagnosis).
After original pharmacological treatment with carbama-
zepine (not tolerated due to side effects), pregabalin, baclo-
fen, and duloxetine, the patient was proposed for a vascular
decompression of a neurovascular contact 7 years after
symptom onset (Figure 2). There was a slight, but transient,
improvement that motivated referral for stereotactic radio-
surgery 1 year after the original surgery. Gamma Knife
radiosurgery was performed with 85 Gy of maximum
dosage. There was an improvement with full remission of
paroxysms and complete withdrawal of oral treatment.
After this procedure, the patient reported consistent
hypesthesia of the right V3 territory. Two years after the
radiosurgery, there was a resurgence of painful paroxysms
that motivated reinitiation of pregabalin (450 mg/day),
duloxetine (60 mg/day), oxcarbazepine (2400 mg/day), and
baclofen (40 mg/day). Lamotrigine was avoided as a ther-
apeutic option due to a concomitant diagnosis of psoriasis.
At this time, the facial pain was classified, according to
Burchiel and colleagues, as a mixed facial pain (sympto-
matic DD-related TN possibly complicated by a trigeminal
deafferentation pain).6 During a 1-year period, there was no
significant reduction on the intensity, frequency, or severity
of the episodes, and an MCS procedure was proposed.
Left MCS was performed (PrimeAdvance, Medtronic,
Minneapolis, Minnesota Figure 1(f) to (h)). The usage of
this device was off-label, with a multidisciplinary group
Figure 1. Brain and cervical MRI performed before the first assessment in the neurology clinic. Axial (a)–(c) and sagittal (d) T2 flair
sequences disclosing hyperintense lesions in the right middle cerebellar peduncle and pons (ipsilateral to the pain side), juxta-ependymal
to the lateral ventricles, and corona radiata typical of MS. No gadolinium enhancement was noted at any time (e) T2-weighted cervical
MRI disclosing multiple cervical spinal cord lesions. (f) Scout view of postoperative CT scan indicating the position of four-contact MCS
electrode in the patient. (g) Identification of the central sulcus (with the postcentral (S) gyrus posteriorly and the precentral (M)
anteriorly) and the frontal inferior sulcus (separating the frontal inferior gyrus from the middle gyrus (F2)). (h) Same identification as
previously described but in the dural plane. The electrode was implanted in the subdural space over the precentral gyrus (M) centered
in the inferior and middle gyrus). MRI: magnetic resonance imaging; CT: computerized tomography; MCS: motor cortex stimulation;
MS: multiple sclerosis.
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oversight. A strip with four electrodes was placed in the
subdural space over the motor cortex, parallel to the central
sulcus (Figure 1(f) to (h)). Surgery was performed under
anesthesia without halogenate agents and without motor
block. The precentral gyrus was identified and intraopera-
tively mapped using neuronavigation (vectorVision Brain-
Lab, Munich, Germany). Regional anatomy of sulci and
gyrus confirmed neuronavigation guidance. The final posi-
tion of the electrode was confirmed with intraoperative
electrical stimulation. The electrode grid was used to per-
form stimulation, and contralateral hemifacial spasm was
monitored with orbicularis oralis electromyography (NIM
Medtronic, Minneapolis, Minnesota). Stimulation was
turned on with electrodes 0, 1, and 2 acting as a cathode
() and electrode 3 as an anode (þ); amplitude of 1.90 V,
frequency of 60 Hz, and pulse duration of 210 ms, prompting
a complete reduction of TN-related drugs. Symptoms
recurred transiently in the first year after surgery, and this
was managed with a voltage increase to 2.70 V with com-
plete resolution. The patient was completely weaned off
medication 9 months after surgery. Another recurrence of
symptoms was noted 2 years after surgery, and this was
managed with a voltage increase to 4.00 V and pulse dura-
tion increase to 300 ms. No further recurrence of symptoms
was noted in the following 1.5 years, and the patient remains
without any oral treatment. Dysarthria was present as a side
effect but only with amplitudes above the therapeutic ones
and with a progressively higher threshold across time.
Discussion
Pharmacological treatment of TN may be unsatisfactory,
particularly when associated with DD.3,5 Medically refrac-
tory DD-related TN has been estimated to affect 1.2 person/
million/year with surgical failures and retreatment rates
reaching up to 90%, with some patients requiring up to
12 surgical procedures.5.
Facial pain outcomes for common surgical approaches
in the context of a DD are poor when compared to
patients with idiopathic TN.7,8 MCS can be an efficient
approach for TN,8 and we report its effectiveness in a
patient with a highly refractory DD-related TN, after
failure of previous procedures.
In DD, TN frequently has concomitant lesions besides
vascular compression, making microvascular decompres-
sion to have a lower probability of effectiveness.9 DD-
related TN has been associated not only with the presence
of lesions in the pontine trigeminal afferents but also with
the presence of lesions in the contralateral insula (a region
involved in pain processing and modulation) and hippo-
campus.10 Connectivity- and plasticity-dependent changes
may contribute to chronic pain maintenance with mechan-
isms independent of trigeminal inputs leading to a lower
short- and long-term effectiveness of rhizotomy tech-
niques.7 While other pain management procedures could
have been considered (repeat the gamma knife or perform-
ing a percutaneous glycerol rhizotomy), we believe that
multiple mechanisms were involved in the pain suffered
by this patient (peripheral lesion in relation to the history
of contact and gamma knife surgery, central demyelination
in the trigeminal tract, and upper-level plasticity demon-
strated by the presence of allodynia). MCS antinociceptive
effect seems to be related to the activation of the descend-
ing inhibitory pain pathway11—a mechanism that is not
explored by most analgesic approaches and that could be
a powerful alternative in pains with multiple neuropathic
lesions (peripheral/root/supratentorial). Albeit the mechan-
isms remain unclarified, MCS is a possible approach for
TN with evidence of long-term effectiveness.12 The long-
term loss of analgesic effect can be counterbalanced by
Figure 2. Schema of pharmacological and surgical treatments during the disease timecourse and patient-reported pain intensity.
Maximal daily doses of drugs: oxcarbazepine 2400 mg, pregabalin 450 mg, baclofen 40 mg, paracetamol 2000 mg, codeine 60 mg,
and duloxetine 60 mg. Carbamazepine unclear in the first period and 800 mg in the second period. Gabapentin is unclear.
Decomp: decompression; radio: radiosurgery; MCS: motor cortex stimulation; VAS: visual analog scale.
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changes in the stimulation parameters. Identifying good
candidates for MCS remains a challenge, and like any other
neuromodulation procedure, short- and long-term compli-
cations (infection, electrode migration, and loss of effect
due to fibrosis) should be considered when this therapy is
proposed to the patient. However, based on the possible
effectiveness, MCS can be considered for patients with
refractory DD-related TN. The development of registries
and longitudinal studies of MCS in TN patients can clarify
the role of this therapy in TN treatment.
Clinical implications
 MCS may be effective in treating refractory
DD-related TN.
 Adjustment of stimulation parameters may help
treating pain relapses.
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